124 results
DEFA14A
ADVM
Adverum Biotechnologies Inc
11 Jun 24
Additional proxy soliciting materials
4:19pm
decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024. The Company expects to make an ordinary … or removal. In connection with his appointment to the Board, Dr. Kiss is expected to be appointed to the Research & Development Committee of the Board
8-K
ADVM
Adverum Biotechnologies Inc
11 Jun 24
Departure of Directors or Certain Officers
4:16pm
with the Appointment, on June 6, 2024, Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board … to be appointed to the Research & Development Committee of the Board.
Szilárd Kiss, M.D., age 49, has been at the Department of Ophthalmology at the Weill
DEFA14A
ADVM
Adverum Biotechnologies Inc
28 May 24
Additional proxy soliciting materials
2:00pm
and Corporate Governance Committee
Chair
Member (Non- Chair)
Research and Development Committee
Chair/Co-Chair
Member (Non- Chair/Co-Chair)
The chair
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
. Adverum expects its cash, cash equivalents and short-term investments to fund operations into late 2025.
Research and development expenses were … $15.4 million for the three months ended March 31, 2024, compared to $21.1 million for the same period in 2023. Research and development expenses
8-K
EX-99.1
3518ehhibsp3dbk
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
8-K
nrjcgbm
5 Feb 24
Entry into a Material Definitive Agreement
5:03pm
8-K/A
j7s0a5zk3 snx
4 Dec 23
Departure of Directors or Certain Officers
4:09pm
8-K
EX-99.1
iff4ed51ferij
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
eskz8
6 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
EX-99.1
x3pw dthhwx2dbyce
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
424B5
zlybz5muv
11 May 23
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
1sz 6roxc4yz
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm